Biologically Active Small Molecules

A potent, orally bioavailable inhibitor of &gamma-secretase that more potently inhibits the cleavage of APP to A&beta40 than signaling through Notch (IC₅₀s = 0.30 and 58 nM, respectively) shows good pharmacokinetics in rats, dogs, and

A potent, orally bioavailable inhibitor of &gamma-secretase that more potently inhibits the cleavage of APP to A&beta40 than signaling through Notch (IC₅₀s = 0.30 and 58 nM, respectively) shows good pharmacokinetics in rats, dogs, and

A potent, orally bioavailable inhibitor of &gamma-secretase that more potently inhibits the cleavage of APP to A&beta40 than signaling through Notch (IC₅₀s = 0.30 and 58 nM, respectively) shows good pharmacokinetics in rats, dogs, and

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.

Inhibitor of NF-&kappaB activation that blocks the phosphorylation of IKK and I&kappaB (IC50 ~ 40 &muM) dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.

Inhibitor of NF-&kappaB activation that blocks the phosphorylation of IKK and I&kappaB (IC50 ~ 40 &muM) dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.